WHO Pharmaceuticals Newsletter 2003, No. 03
(2003; 14 pages) View the PDF document
Table of Contents
Open this folder and view contentsREGULATORY MATTERS
Close this folderSAFETY OF MEDICINES
View the documentANTIRETRO-VIRALS - Benefit/Risk balance remains strongly positive for combination antiretroviral therapy
View the documentCYPROTERONE ACETATE & ETHINYL-ESTRADIOL - Update on risk of venous thromboembolism
View the documentDIETHYL-STILBESTROL - Gynaecological and obstetric complications after in utero exposure
View the documentEPHEDRA - Moves to reduce risks of ephedra-containing products
View the documentFLUTICASONE PROPIONATE - Reports of adrenal crisis
View the documentGRAPEFRUIT JUICE - Revised advice from ADRAC
View the documentHORMONE REPLACEMENT THERAPY (HRT) - Risk of dementia
View the documentOMEPRAZOLE, RABEPRAZOLE - Reports of interstitial nephritis
View the documentROFECOXIB, CELECOXIB - Case reports support causal association with liver toxicity
View the documentROSIGLITA-ZONE, PIOGLITAZONE - Adverse reactions update
View the documentSOMATROPIN - Not to be authorized for AIDS-related wasting syndrome
Open this folder and view contentsCURRENT CONCERNS
Open this folder and view contentsDRUGS OF INTEREST
Open this folder and view contentsFEATURE
 

FLUTICASONE PROPIONATE - Reports of adrenal crisis

Australia. Adverse Drug Reactions Advisory Committee (ADRAC) in Australia has received 10 reports of inhaled corticosteroid-associated adrenal crisis. Eight cases involved children aged 3 10 years who had received fluticasone propionate (Flixotide) 250 1500 µg/day; in six cases, the daily dose was > 500µg, the upper limit recommended by The Thoracic Society of Australia and New Zealand and by The National Asthma Council in Australia, before referral to a respiratory physician. The committee notes that higher fluticasone propionate doses may not confer greater efficacy and prescribers are reminded that "inhaled corticosteroids should be given at the lowest effective dose and reviewed regularly".

Reports in WHO-file: Adrenal insufficiency 100

Reference:
Australian Adverse Drug Reactions Bulletin 22: 6, Apr 2003.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 1, 2019